Fine tuning a well-oiled machine: Influence of NK1.1 and NKG2D on NKT cell development and function

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 260-266

  Joshi, Sunil K ^a,b   Lang, Mark L ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OLD DOMINION UNIVERSITY   (United States)

Author keywords

Adaptive immunity; NK1.1; NKG2D; NKT cells; Pathogenesis

Indexed keywords

CD1D ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; EARLY GROWTH RESPONSE FACTOR 2; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NK1.1; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN C MYB; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; MICROENVIRONMENT; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADAPTIVE IMMUNITY; NK1.1; NKG2D; NKT CELLS; PATHOGENESIS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, LY; AUTOIMMUNE DISEASES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; NATURAL KILLER T-CELLS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTOR CROSS-TALK;

EID: 84880184524     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.05.022     Document Type: Review

References (99)

1. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513. (Pubitemid 37174539)
2. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9. (Pubitemid 27516282)
3. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol 2011;12:966-74.
4. Wingender G, Rogers P, Batzer G, Lee MS, Bai D, et al. Invariant NKT cells are required for airway inflammation induced by environmental antigens. J Exp Med 2011;208:1151-62.
5. Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 1999;17:297-329. (Pubitemid 29241127)
6. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005;23:877-900. (Pubitemid 40563188)
7. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007;25:297-336. (Pubitemid 46697911)
8. Zajonc DM, Maricic I, Wu D, Halder R, Roy K, et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med 2005;202:1517-26. (Pubitemid 41746598)
9. Adams EJ, Luoma AM. The yin and yang of CD1d recognition. Nat Immunol 2012;13:814-5.
10. Lopez-Sagaseta J, Sibener LV, Kung JE, Gumperz J, Adams EJ. Lysophospholipid presentation by CD1d and recognition by a human Natural Killer T-cell receptor. EMBO J 2012;31:2047-59.
11. Adams EJ, Lopez-Sagaseta J. The immutable recognition of CD1d. Immunity 2011;34:281-3.
12. Wun KS, Cameron G, Patel O, Pang SS, Pellicci DG, et al. A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells. Immunity 2011;34:327-39.
13. Uldrich AP, Patel O, Cameron G, Pellicci DG, Day EB, et al. A semi-invariant Valpha10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat Immunol 2011;12: 616-23.
14. Patel O, Pellicci DG, Gras S, Sandoval-Romero ML, Uldrich AP, et al. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat Immunol 2012;13:857-63.
15. Rhost S, Lofbom L, Rynmark BM, Pei B, Mansson JE, et al. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte. Eur J Immunol 2012;42(11):2851-60.
16. Rhost S, Sedimbi S, Kadri N, Cardell SL. Immunomodulatory type II natural killer T lymphocytes in health and disease. Scand J Immunol 2012;76:246-55.
17. Patel O, Pellicci DG, Uldrich AP, Sullivan LC, Bhati M, et al. Vbeta2 natural killer T cell antigen receptor-mediated recognition of CD1d-glycolipid antigen. Proc Natl Acad Sci U S A 2011;108:19007-12.
18. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005;202:1627-33. (Pubitemid 41815868)
19. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 2007;117:2302-12. (Pubitemid 47219575)
20. Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M. Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int Immunol 1995;7:1157-61.
21. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, et al. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863-5.
22. Issazadeh-Navikas S. NKT cell self-reactivity: evolutionary master key of immune homeostasis? J Mol Cell Biol 2012;4:70-8.
23. Brennan PJ, Tatituri RV, Brigl M, Kim EY, Tuli A, et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol 2011;12:1202-11.
24. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, et al. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J Exp Med 2011;208:1163-77.
25. Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, et al. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A 2006;103:11252-7. (Pubitemid 44156505)
26. Fujii S, Shimizu K, Hemmi H, Steinman RM. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 2007;220:183-98. (Pubitemid 350045564)
27. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 2007;178:2853-61. (Pubitemid 46333163)
28. Leadbetter EA, Brigl M, Illarionov P, Cohen N, Luteran MC, et al. NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci U S A 2008;105: 8339-44. (Pubitemid 351904757)
29. Schofield L, McConville MJ, Hansen D, Campbell AS, Fraser-Reid B, et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 1999;283:225-9.
30. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, et al. Alpha- galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2005;175:3309-17.
31. Lang GA, Exley MA, LangML. The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology 2006;119:116-25. (Pubitemid 44201161)
32. Devera TS, Aye LM, Lang GA, Joshi SK, Ballard JD, et al. CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies. Infect Immun 2010;78:1610-7.
33. Belperron AA, Dailey CM, Bockenstedt LK. Infection-induced marginal zone B cell production of Borrelia hermsii-specific antibody is impaired in the absence of CD1d. J Immunol 2005;174:5681-6. (Pubitemid 40593210)
34. Kobrynski LJ, Sousa AO, Nahmias AJ, Lee FK. Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cells. J Immunol 2005;174:1787-90. (Pubitemid 40223917)
35. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A 2007;104:3984-9. (Pubitemid 47181565)
36. Wermeling F, Lind SM, Jordo ED, Cardell SL, Karlsson MC. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med 2010;207:943-52.
37. Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C. Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012;36:477-90.
38. Lang GA, Devera TS, Lang ML. Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production. Blood 2008;111:2158-62. (Pubitemid 351451529)
39. Joshi SK, Lang GA, Devera TS, Johnson AM, Kovats S, Lang ML. Differential contribution of dendritic cell CD1d to NKT cell-enhanced humoral immunity and CD8+ T cell activation. J Leukoc Biol 2012;91(5):783-90.
40. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-74. (Pubitemid 40563170)
41. Kuroki K, Furukawa A, Maenaka K. Molecular recognition of paired receptors in the immune system. Front Microbiol 2012;3:429.
42. Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol 2003;4:801-7. (Pubitemid 36986765)
43. Reichlin A, Yokoyama WM. Natural killer cell proliferation induced by anti-NK1.1 and IL-2. Immunol Cell Biol 1998;76:143-52. (Pubitemid 28223621)
44. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol 2002;14:306-11. (Pubitemid 34327971)
45. Zafirova B, Wensveen FM, Gulin M, Polic B. Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 2011;68:3519-29.
46. Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A 2005;102:7641-6. (Pubitemid 40741024)
47. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007;7:737-44. (Pubitemid 47327391)
48. Obeidy P, Sharland AF. NKG2D and its ligands. Int J Biochem Cell Biol 2009;41: 2364-7.
49. Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol 2013;190:2455-63.
50. Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 2011;71: 2066-76.
51. Das R, Sant'Angelo DB, Nichols KE. Transcriptional control of invariant NKT cell development. Immunol Rev 2010;238:195-215.
52. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010;11:197-206.
53. Griewank K, Borowski C, Rietdijk S, Wang N, Julien A, et al. Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity 2007;27:751-62. (Pubitemid 350102258)
54. Gapin L, Matsuda JL, Surh CD, Kronenberg M. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2001;2:971-8. (Pubitemid 32976171)
55. Cui J, Shin T, Kawano T, Sato H, Kondo E, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-6. (Pubitemid 27516281)
56. Zhou D, Mattner J, Cantu 3rd C, Schrantz N, Yin N, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306:1786-9. (Pubitemid 39601398)
57. Hu T, Gimferrer I, Simmons A, Wiest D, Alberola-Ila J. The Ras/MAPK pathway is required for generation of iNKT cells. PLoS One 2011;6:e19890.
58. Hu T, Simmons A, Yuan J, Bender TP, Alberola-Ila J. The transcription factor c-Myb primes CD4 + CD8+ immature thymocytes for selection into the iNKT lineage. Nat Immunol 2010;11:435-41.
59. Kronenberg M, Engel I. On the road: progress in finding the unique pathway of invariant NKT cell differentiation. Curr Opin Immunol 2007;19:186-93. (Pubitemid 46356970)
60. Savage AK, Constantinides MG, Han J, Picard D, Martin E, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008;29:391-403.
61. Eidson M,WahlstromJ, Beaulieu AM, Zaidi B, Carsons SE, et al. Altered development of NKT cells, gammadelta T cells, CD8 T cells and NK cells in a PLZF deficient patient. PLoS One 2011;6:e24441.
62. O'Reilly V, Zeng SG, Bricard G, Atzberger A, Hogan AE, et al. Distinct and overlapping effector functions of expanded human CD4+, CD8alpha+ and CD4-CD8alpha-invariant natural killer T cells. PLoS One 2011;6:e28648.
63. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A. A thymic precursor to the NK T cell lineage. Science 2002;296:553-5. (Pubitemid 34408679)
64. Gadue P, Stein PL. NK T cell precursors exhibit differential cytokine regulation and require Itk for efficient maturation. J Immunol 2002;169:2397-406. (Pubitemid 34920982)
65. Berzins SP, McNab FW, Jones CM, Smyth MJ, Godfrey DI. Long-term retention of mature NK1.1+ NKT cells in the thymus. J Immunol 2006;176:4059-65. (Pubitemid 44264384)
66. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008;9:495-502. (Pubitemid 351560518)
67. Subleski JJ, Wiltrout RH, Weiss JM. Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. J Autoimmun 2009;33:275-81.
68. Ortaldo JR, Winkler-Pickett R, Wigginton J, Horner M, Bere EW, et al. Regulation of ITAM-positive receptors: role of IL-12 and IL-18. Blood 2006;107:1468-75. (Pubitemid 43242383)
69. Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1-NKT cell population. Proc Natl Acad Sci U S A 2008;105:11287-92.
70. Doisne JM, Becourt C, Amniai L, Duarte N, Le Luduec JB, et al. Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)t+ and respond preferentially under inflammatory conditions. J Immunol 2009;183:2142-9.
71. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007;204:995-1001. (Pubitemid 46798144)
72. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 2008;180: 5167-71.
73. Terashima A, Watarai H, Inoue S, Sekine E, Nakagawa R, et al. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J Exp Med 2008;205:2727-33.
74. Kuylenstierna C, Bjorkstrom NK, Andersson SK, Sahlstrom P, Bosnjak L, et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol 2011;41:1913-23.
75. Wang H, Yang D, Xu W, Wang Y, Ruan Z, et al. Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients. Immunol Lett 2008;120:65-71.
76. Guo H, Xu B, Gao L, Sun X, Qu X, et al. High frequency of activated natural killer and natural killer T-cells in patients with new onset of type 2 diabetes mellitus. Exp Biol Med (Maywood) 2012;237:556-62.
77. Li WX, Pan HF, Hu JL, Wang CZ, Zhang N, et al. Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus. Clin Rheumatol 2010;29:315-23.
78. Miko E, Szereday L, Barakonyi A, Jarkovich A, Varga P, et al. The role of invariant NKT cells in pre-eclampsia. Am J Reprod Immunol 2008;60:118-26. (Pubitemid 352044145)
79. Joshi SK, Lang GA, Larabee JL, Devera TS, Aye LM, et al. Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy. PLoS Pathog 2009;5:e1000588.
80. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, et al. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002;16:583-94. (Pubitemid 34442582)
81. Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci U S A 2007;104:18187-92. (Pubitemid 350210842)
82. Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 2005;202:1507-16. (Pubitemid 41746597)
83. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002;3:867-74.
84. Eagle RA, Jafferji I, Barrow AD. Beyond stressed self: evidence for NKG2D ligand expression on healthy cells. Curr Immunol Rev 2009;5:22-34.
85. Lang ML. How do natural killer T cells help B cells? Expert Rev Vaccines 2009;8: 1109-21.
86. Juno JA, Keynan Y, Fowke KR. Invariant NKT Cells: regulation and function during viral infection. PLoS Pathog 2012;8:e1002838.
87. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011;11:131-42.
88. Swann JB, Coquet JM, Smyth MJ, Godfrey DI. CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol 2007;314:293-323.
89. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-7. (Pubitemid 38339089)
90. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med 2005;202:1623-6. (Pubitemid 41815867)
91. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-36. (Pubitemid 34461507)
92. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007;178:2827-34. (Pubitemid 46333160)
93. Goto M, Murakawa M, Kadoshima-Yamaoka K, Tanaka Y, Nagahira K, et al. Murine NKT cells produce Th17 cytokine interleukin-22. Cell Immunol 2009;254:81-4.
94. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002;195:637-41. (Pubitemid 34461508)
95. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003;171:5140-7. (Pubitemid 37432797)
96. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005;202: 1279-88. (Pubitemid 41586958)
97. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-27. (Pubitemid 34747317)
98. Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C, et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 2003;197: 1051-7. (Pubitemid 36523203)
99. Devera TS, Shah HB, Lang GA, Lang ML. Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers. Eur J Immunol 2008;38:1001-11.